T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017

  • ID: 4429848
  • Report
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Atox Bio Ltd
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • TheraMAB LLC
  • MORE
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017

Summary

According to the recently published report 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017'; T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

The report 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Systemic Lupus Erythematosus, Acute Renal Failure (ARF) (Acute Kidney Injury), Arthritis, B-Cell Chronic Lymphocytic Leukemia, Encephalomyelitis, Gastrointestinal Radiation Toxicity, Hypersensitivity, Kidney Transplant Rejection, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Skin And Soft Tissue Infections, Solid Tumor, Stem Cell Transplantation and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
  • The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Atox Bio Ltd
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • TheraMAB LLC
  • MORE
Introduction

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development

Atox Bio Ltd

Bristol-Myers Squibb Co

Five Prime Therapeutics Inc

Johnson & Johnson

TheraMAB LLC

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles

ALPN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPT-155 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lulizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize CD278 and CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize CD278 and CD28 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAB-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones

Featured News & Press Releases

Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation

Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155

Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections

Sep 20, 2017: Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting

Jun 14, 2017: Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model

May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned

Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology

Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections

Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections

Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control

Apr 15, 2015: Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Feb 12, 2015: Two major scientific articles validate Effimune’s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Atox Bio Ltd, H2 2017

Pipeline by Bristol-Myers Squibb Co, H2 2017

Pipeline by Five Prime Therapeutics Inc, H2 2017

Pipeline by Johnson & Johnson, H2 2017

Pipeline by TheraMAB LLC, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Atox Bio Ltd
  • Bristol-Myers Squibb Co
  • Five Prime Therapeutics Inc
  • Johnson & Johnson
  • TheraMAB LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll